We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Hologic (HOLX - Free Report) closed at $65.51, marking a -1.82% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.3%. Elsewhere, the Dow lost 0.48%, while the tech-heavy Nasdaq added 0.03%.
Heading into today, shares of the medical device maker had lost 1.81% over the past month, lagging the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09%.
The investment community will be closely monitoring the performance of Hologic in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $1.1, reflecting a 8.91% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.03 billion, showing a 4.6% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.23 per share and revenue of $4.08 billion. These totals would mark changes of +3.68% and +1.34%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Hologic. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% higher. Right now, Hologic possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Hologic has a Forward P/E ratio of 15.77 right now. This valuation marks a discount compared to its industry average Forward P/E of 23.97.
We can also see that HOLX currently has a PEG ratio of 2.42. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.57.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Hologic (HOLX - Free Report) closed at $65.51, marking a -1.82% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.3%. Elsewhere, the Dow lost 0.48%, while the tech-heavy Nasdaq added 0.03%.
Heading into today, shares of the medical device maker had lost 1.81% over the past month, lagging the Medical sector's gain of 7.07% and the S&P 500's gain of 2.09%.
The investment community will be closely monitoring the performance of Hologic in its forthcoming earnings report. The company's earnings per share (EPS) are projected to be $1.1, reflecting a 8.91% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $1.03 billion, showing a 4.6% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $4.23 per share and revenue of $4.08 billion. These totals would mark changes of +3.68% and +1.34%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for Hologic. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.07% higher. Right now, Hologic possesses a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Hologic has a Forward P/E ratio of 15.77 right now. This valuation marks a discount compared to its industry average Forward P/E of 23.97.
We can also see that HOLX currently has a PEG ratio of 2.42. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Instruments industry was having an average PEG ratio of 2.57.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.